AU1040600A - Use of tgf-beta inhibitors for treating cerebral disorders - Google Patents

Use of tgf-beta inhibitors for treating cerebral disorders

Info

Publication number
AU1040600A
AU1040600A AU10406/00A AU1040600A AU1040600A AU 1040600 A AU1040600 A AU 1040600A AU 10406/00 A AU10406/00 A AU 10406/00A AU 1040600 A AU1040600 A AU 1040600A AU 1040600 A AU1040600 A AU 1040600A
Authority
AU
Australia
Prior art keywords
tgf
treating cerebral
beta inhibitors
cerebral disorders
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10406/00A
Inventor
Kerstin Kriegelstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH
Original Assignee
Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH filed Critical Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH
Publication of AU1040600A publication Critical patent/AU1040600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU10406/00A 1999-03-16 1999-10-19 Use of tgf-beta inhibitors for treating cerebral disorders Abandoned AU1040600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99104033 1999-03-16
EP99104033 1999-03-16
PCT/EP1999/007897 WO2000054804A1 (en) 1999-03-16 1999-10-19 Use of tgf-beta inhibitors for treating cerebral disorders

Publications (1)

Publication Number Publication Date
AU1040600A true AU1040600A (en) 2000-10-04

Family

ID=8237677

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10406/00A Abandoned AU1040600A (en) 1999-03-16 1999-10-19 Use of tgf-beta inhibitors for treating cerebral disorders

Country Status (2)

Country Link
AU (1) AU1040600A (en)
WO (1) WO2000054804A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61112018A (en) * 1984-11-06 1986-05-30 Mitsubishi Chem Ind Ltd Agent for promoting fibrinolysis
AU3943793A (en) * 1992-04-01 1993-11-08 Whittier Institute For Diabetes And Endocrinology, The Methods of inhibiting or enhancing scar formation in the CNS
US5399487A (en) * 1993-03-04 1995-03-21 Haematologic Technologies, Inc. 6-peptidylamino-1-naphthalenesulfonamides useful as fluorogenic proteolytic enzyme substrates
WO1995010611A1 (en) * 1993-10-14 1995-04-20 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells

Also Published As

Publication number Publication date
WO2000054804A1 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
AU2001261637A1 (en) Apparatus for treatment of spinal disorders
AU8003800A (en) Methods and compositions for treating neurobehavioral disorders
AU2002224417A1 (en) Methods for treating il-18 mediated disorders
AU2001247474A1 (en) Compounds for the treatment of psychiatric or substance abuse disorders
AU6462500A (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
IL153425A0 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
AU5309400A (en) Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
AU6910600A (en) Methods for the treatment of mental disorders
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU3977700A (en) Method of treating neurological disorders
AU5042000A (en) Methods of treating proliferative disorders
AU2002362115A1 (en) Composition and methods for treatment of neurological disorders
AU4552200A (en) Method of treating psychotic disorders
AU5912900A (en) Quinuclidine derivatives for treatment of neurological disorders
AU1653101A (en) Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders
AU3899100A (en) Treatment of hyperactivity disorders
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
AU1040600A (en) Use of tgf-beta inhibitors for treating cerebral disorders
AU2000270300A1 (en) Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
AU2002221566A1 (en) Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
AU4021700A (en) Methods of use of beta1-integrin inhibitors
AU8626398A (en) Inhibitors of the phosphodiesterase-4 for the treatment of allergic rhinitis
AU2003297259A1 (en) Methods and compositions for treating neurological disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase